EHA25 Virtual Congress - CALQUENCE® Trial Results for Chronic Lymphocytic Leukemia
Dr. Carlos Doti discusses the results from two trials - Ph.2 ACE-CL-001 and Ph.3 ASCEND, that was presented at the virtual edition of the European Hematology Association's (EHA25) Annual Congress, showing long-term efficacy and tolerability of CALQUENCE® (acalabrutinib) in patients with chronic lymphocytic leukemia (CLL).
#EHA25 #CALQUENCE #ChronicLymphocyticLeukemia
Visit our website
www.healtprofessionalradio.com.au
Follow us on our social media channels
Facebook: https://www.facebook.com/hprfm/
Twitter: https://twitter.com/HealthProRadio
Google+: https://plus.google.com/+HealthProfes...
Pinterest: https://www.pinterest.com/HealthProRa...
Linkedin: https://www.linkedin.com/company/heal...
Instagram: https://www.instagram.com/healthprofe...
Subscribe to our podcast channels
Soundcloud: https://soundcloud.com/healthprofessi...
Itunes: https://itunes.apple.com/nz/podcast/h...
Support us on Patreon
https://www.patreon.com/HPR
-
Category
No comments found